NOVA:FRA
Novo Nordisk A/S
36,92 €
arrow_upward
+0,05%(+0,020) 1D
10 noy, 22:00:00 GMT+1 · EUR
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoNOVA üçün ən vacib statistik məlumatlar yaradılır...
Açın
37,22 €
Yüksək
37,22 €
Aşağı
36,54 €
Bazar kapitalizasiyası
135,60 mlrd
Ortalama həcm
725,00
Həcm
152,00
52 həftəlik ən yüksək
54,80 €
52 həftəlik ən aşağı
30,45 €
İşçilərin sayı
67K
Açın
37,22 €
Yüksək
37,22 €
Aşağı
36,54 €
Bazar kapitalizasiyası
135,60 mlrd
Ortalama həcm
725,00
Həcm
152,00
52 həftəlik ən yüksək
54,80 €
52 həftəlik ən aşağı
30,45 €
İşçilərin sayı
67K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
Foreign Policy Journal
·
3 saat öncə
European ADR Selloff Hits Broad Range Of Stocks Tuesday, With Novo Nordisk (NYSE: NVO) And Eni (NYSE: E) Among Hardest Hit
The Motley Fool
·
8 saat öncə
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
International Business Times
·
11 saat öncə
The FDA Ordered GLP-1 Vision-Loss Warnings For Some Products. Shares of Eli Lilly and Novo Nordisk Were Unfazed.
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S haqqında
Baş İcraçı DirektorMike Doustdar
İşçilər66,7K
Təsis Tarixi1923
Baş OfisBagsværd, Capital Region of Denmark, Danimarka
SektorHealth Care
SənayePharmaceutical industry
Veb-saytnovonordisk.com